Cardiac Protection of Valsartan on Juvenile Rats with Heart Failure by Inhibiting Activity of CaMKII via Attenuating Phosphorylation

Abstract EN

Background.

This study was undertaken to determine relative contributions of phosphorylation and oxidation to the increased activity of calcium/calmodulin-stimulated protein kinase II (CaMKII) in juveniles with cardiac myocyte dysfunction due to increased pressure overload.

Methods.

Juvenile rats underwent abdominal aortic constriction to induce heart failure.

Four weeks after surgery, rats were then randomly divided into two groups: one group given valsartan (HF + Val) and the other group given placebo (HF + PBO).

Simultaneously, the sham-operated rats were randomly given valsartan (Sham + Val) or placebo (Sham + PBO).

After 4 weeks of treatment, Western blot analysis was employed to quantify CaMKII and relative calcium handling proteins (RyR2 and PLN) in all groups.

Results.

The deteriorated cardiac function was reversed by valsartan treatment.

In ventricular muscle cells of group HF + PBO, Thr287 phosphorylation of CaMKII and S2808 phosphorylation of RyR2 and PLN were increased and S16 phosphorylation of PLN was decreased compared to the other groups, while Met281 oxidation was not significantly elevated.

In addition, these changes in the expression of calcium handling proteins were ameliorated by valsartan administration.

Conclusions.

The phosphorylation of Thr286 is associated with the early activation of CaMKII rather than the oxidation of Met281.